Cancer Stem Cell News Volume 11.10 | Mar 16 2022


    2022-03-16 | CSCN 11.10

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.10 – 16 March, 2022

    Cancer Stem Cell Regulated Phenotypic Plasticity Protects Metastasized Cancer Cells from Ferroptosis

    Co-implantation with breast CSCs (BCSCs) decreased the tumor-initiating capacity yet increased metastasis of accompanying cancer cells, wherein DKK1 was identified as a pivotal factor secreted by BCSCs for such functions.
    [Nature Communications]

    Full Article

    Explore virtual support and resources to stay productive and connected with your field.
    PUBLICATIONSRanked by the impact factor of the journal

    A Reversible Metabolic Stress-Sensitive Regulation of CRMP2A Orchestrates EMT/Stemness and Increases Metastatic Potential in Cancer

    Investigators showed that collapsin response mediator protein 2A (CRMP2A) was unexpectedly and reversibly induced in cancer cells in response to multiple metabolic stresses, including low glucose and hypoxia, and inhibited EMT/stemness.
    [Cell Reports]

    Full ArticleGraphical Abstract

    SIK2 Maintains Breast Cancer Stemness by Phosphorylating LRP6 and Activating Wnt/β-Catenin Signaling

    Researchers demonstrated a novel mechanism whereby Wnt/β-catenin signaling pathway was regulated by different kinases in response to metabolic requirement of CSCs, and suggest that SIK2 inhibition may potentially be a strategy for eliminating breast CSCs.


    Lon Upregulation Contributes to Cisplatin Resistance by Triggering NCLX-Mediated Mitochondrial Ca2+ Release in Cancer Cells

    Scientists reported the role of Lon in the response to cisplatin-induced mitochondrial DNA damage and oxidative stress, which conferred cancer cells on cisplatin resistance via modulating calcium levels in mitochondria and cytosol.
    [Cell Death & Disease]

    Full Article

    Disruption of the Crypt Niche Promotes Outgrowth of Mutated Colorectal Tumor Stem Cells

    While azoxymethane delivery in vivo under non-adenoma-forming conditions yielded phenotypically normal mucosa and organoids derived thereof, niche injury ex vivo by progressive dextran sulfate sodium dose escalation facilitated outgrowth of Wnt-independent dysplastic organoids.
    [JCI Insight]

    Full Article

    Niclosamide Induces miR-148a to Inhibit PXR and Sensitize Colon Cancer Stem Cells to Chemotherapy

    The authors identified miR-148a as a targetable element upstream of pregnane X receptor (PXR) signaling in CSCs, which when over-expressed decreased PXR expression and impaired tumor relapse after chemotherapy in mouse tumor xenografts.
    [Stem Cell Reports]

    Full Article

    Asymmetric Pericentrosomal CD133 Endosomes Induce the Unequal Autophagic Activity During Cytokinesis in CD133-Positive Human Neuroblastoma Cells

    Scientists suggested that the asymmetric distribution of pericentrosomal CD133 endosomes induced the symmetry breaking of autophagic activity during cytokinesis in cooperation with nuclear β-catenin.
    [Stem Cells]

    Full Article
    Graphical Abstract

    AC010973.2 Promotes Cell Proliferation and Is One of Six Stemness-Related Genes That Predict Overall Survival of Renal Clear Cell Carcinoma

    Researchers revealed that the stemness-related gene AC01097.3 was closely associated with the survival of renal clear cell carcinoma patients.
    [Scientific Reports]

    Full Article

    “Double Hit” Strategy: Removal of Sialic Acid from the Dendritic Cell Surface and Loading with CD44+/CD24/Low Cell Lysate Inhibits Tumor Growth and Metastasis by Targeting Breast Cancer Stem Cells

    The authors revealed that sialic acid removal and loading with CSC antigens induced significant molecular, morphological, and functional changes in dendritic cells (DCs) and that this new DC identity may be considered for future combined immunotherapy strategies against breast tumors.
    [International Immunopharmacology]

    AbstractGraphical Abstract

    Elevated Expression of RAB3B Plays Important Roles in Chemoresistance and Metastatic Potential of Hepatoma Cells

    RAB3B was identified as an up-regulated gene in both cancer stem-like sphere cells and prognostically poor hepatocellular carcinoma by RNA-sequencing.
    [BMC Cancer]

    Full Article

    Diphenyleneiodonium Efficiently Inhibits the Characteristics of a Cancer Stem Cell Model Derived from Induced Pluripotent Stem Cells

    Researchers evaluated diphenyleneiodonium as an anticancer drug by assessing its effect on an induced pluripotent stem-derived CSC model in both 2D and 3D culture conditions.
    [Cell Biochemistry and Function]


    Keep current with the latest in ESC and iPSC research.

    Cancer-Inducing Niche: The Force of Chronic Inflammation

    The authors suggest that chronic diseases, including obesity and diabetes, establish the cancer-inducing niche that drives the undifferentiated/progenitor cells into CSCs, which then develop malignant tumours in vivo.
    [British Journal of Cancer]


    Targeting Tumor Associated Macrophages in Hepatocellular Carcinoma

    Investigators summarize what we know about tumor-associated macrophages (TAMs) and hepatocellular carcinoma (HCC), discussing the roles of TAMs in HCC development and the possible approaches for TAMs-targeted therapy as potential targets for HCC treatment.
    [Biochemical Pharmacology]

    AbstractGraphical Abstract

    Deciphering Cancer Stem Cells in Liver Cancers: New Tools with Improved Resolution

    Scientists review the evolution of tools to evaluate CSCs in liver cancers, discuss their contributions and limitations, as well as their combined and complementary utilization with techniques like human tumor organoid culture.



    Fralin Biomedical Research Institute at VTC researcher is Virginia Tech’s first NIH Outstanding Investigator Award recipient

    Robert Gourdie, a cardiovascular scientist at the Fralin Biomedical Research Institute at Virginia Tech Carilion School of Medicine (VTC), is the first Virginia Tech researcher to receive an Outstanding Investigator Award from the National Institutes of Health (NIH).
    [Virginia Tech]

    Press Release

    LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase III OlympiA Trial

    AstraZeneca and Merck announced additional positive results from the Phase III OlympiA trial, where LYNPARZA demonstrated a statistically significant improvement in overall survival for the treatment of high-risk early breast cancer.

    Press Release

    Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (Pembrolizumab) in Combination with LYNPARZA® (Olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility

    Merck announced that it will stop the Phase II KEYLYNK-010 trial investigating KEYTRUDA for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide.

    Press Release


    EMBO: Microbial Infections and Human Cancer

    April 6 – 9, 2022
    Heidelberg, Germany

    > See All Events


    Principal Scientific Researcher – Cell and Tissue Genomics

    Genentech, Inc. – South San Francisco, California, United States

    Senior Associate Scientist – Biology

    Gilead Sciences – Foster City, California, United States

    Postdoctoral Scholar – Cancer Cell Identity

    Oregon Health and Science University – Portland, Oregon, United States

    PhD Scientist – Oncology

    University of Virginia School of Medicine – Charlottesville, Virginia, United States

    Senior Research Investigator – Biomedical Sciences

    University of Pennsylvania – Philadelphia, Pennsylvania, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter